In the Rheumatology Unit, University of Modena and Reggio Emilia Medical School, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Italy, Dilia Giuggioli, MD, PhD, is Associate Professor; Amelia Spinella, MD, PhD, is Medical Assistant; Marco de Pinto, MD, is Resident; Mascia Maria Teresa, MD, is Associate Professor; and Carlo Salvarani, MD, is Full Professor. The authors have disclosed no financial relationships related to this article. Submitted December 21, 2020; accepted in revised form March 15, 2021; published online ahead of print October 6, 2021.
Adv Skin Wound Care. 2022 Feb 1;35(2):123-124. doi: 10.1097/01.ASW.0000795240.63966.53.
In 2019, the novel SARS-CoV-2 infection emerged, causing the disease called COVID-19, which primarily affects the respiratory tract and lung at alveolar and interstitial levels. Systemic sclerosis (SSc) is an autoimmune connective disease characterized by vascular abnormalities and diffuse and progressive fibrosis of the skin and internal organs. Raynaud phenomenon (RP) occurs in virtually all patients affected by SSc and, in most cases, is an onset symptom of the disease; that is, RP may appear several years before overt illness. Although the exact pathophysiologic pathways leading to RP and SSc are still unknown, several infectious agents, especially viruses, have been suggested as possible triggering factors. Here, the authors describe the first case of RP secondary to SSc following SARS-CoV-2 infection.
2019 年,新型 SARS-CoV-2 感染出现,导致 COVID-19 疾病,主要影响呼吸道和肺泡及肺间质水平的肺。系统性硬化症(SSc)是一种自身免疫性结缔组织疾病,其特征是血管异常以及皮肤和内脏器官弥漫性和进行性纤维化。雷诺现象(RP)几乎发生在所有受 SSc 影响的患者中,并且在大多数情况下是该疾病的起始症状;也就是说,RP 可能在明显疾病出现之前几年就出现。尽管导致 RP 和 SSc 的确切病理生理途径仍不清楚,但已经提出了几种感染因子,尤其是病毒,作为可能的触发因素。在这里,作者描述了首例 SARS-CoV-2 感染继发于 SSc 的 RP 病例。